Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Why Analysts Say the CytomX Story Is Evolving After Recent Clinical Momentum and Price Target Hike [Yahoo! Finance]

CytomX Therapeutics, Inc. (CTMX) 
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytomx.com
Company Research Source: Yahoo! Finance
CytomX Therapeutics has recently seen its consensus analyst price target rise from $6.14 to $7.07 per share, reflecting growing optimism about the company's outlook as its lead asset moves forward in clinical development. This upward revision comes as investors take note of encouraging data and increased confidence in the potential of CX-2051 within the highly competitive colorectal cancer market. Stay tuned to discover how you can monitor these shifting expectations and keep up with future updates to the CytomX narrative. Show less Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CTMX alerts
Opt-in for
CTMX alerts

from News Quantified
Opt-in for
CTMX alerts

from News Quantified